Every 8-K that Eikon Therapeutics, Inc. (EIKN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EIKN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EIKN filings page.
Eikon Therapeutics provides a detailed update on its clinical-stage pipeline and technology platform. The company describes EIK1001, a TLR7/8 dual-agonist being tested in the Phase 2 TeLuRide-005 NSCLC study, where objective response rate was 63.1% and disease control rate 90.8% across 65 efficacy-evaluable participants as of May 4, 2026, with generally manageable safety alongside pembrolizumab and chemotherapy. A Phase 2/3 registrational melanoma trial (TeLuRide-006) and a Phase 2/3 NSCLC trial (TeLuRide-008) are underway with multiple data readouts and interim analyses planned between the second half of 2026 and the first half of 2027.
The update also highlights EIK1003, a PARP1-selective inhibitor, showing monotherapy objective response rate of 14.3% (7 of 49 evaluable participants) and 24.5% in combination with paclitaxel (13 of 53), with no treatment-related deaths reported. EIK1005, a WRN inhibitor for MSI-high cancers, has early clinical safety data supporting a 50 mg starting dose and a half-life of 9.4 days. EIK1006, an AR antagonist, is progressing through preclinical work toward a projected IND submission by the end of 2026. Eikon emphasizes its single-molecule tracking technology, machine-learning–guided design, and an experienced leadership team.
Eikon Therapeutics, Inc. reported second quarter 2026 results and extensive clinical progress across its oncology pipeline. The company ended the quarter with $531.2 million in cash, cash equivalents and marketable securities and expects this balance to fund operations into the second half of 2027. Net loss attributable to common stockholders was $88.4 million, compared with $105.2 million a year earlier.
Research and development expenses for the quarter were $75.5 million, up from $69.2 million, reflecting increased clinical trial activity. General and administrative expenses declined sharply to $17.9 million from $40.5 million, primarily due to prior-year impairments that did not recur. Total stockholders’ equity improved to $466.5 million at June 30, 2026, from a deficit of $(879.0) million at December 31, 2025.
Clinically, Eikon highlighted seven accepted abstracts for ESMO 2026 covering all four current clinical candidates, encouraging combination data for EIK1001 in NSCLC and melanoma, and advancing Phase 1/2 programs for PARP1 inhibitors EIK1003 and EIK1004, WRN helicase inhibitor EIK1005, and planned IND submission for AR antagonist EIK1006 by year-end 2026.
Eikon Therapeutics, Inc. reported that board members Leon Chen, Ph.D. and Joshua Wolfe resigned from its Board of Directors, effective July 31, 2026. The company states that their resignations were not due to any disagreement regarding operations, policies, or practices.
Eikon Therapeutics is a Delaware corporation whose common stock, par value $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol EIKN. The report documenting these director changes is signed by Chief Financial Officer Alfred Bowie, Ph.D., on August 3, 2026.
Eikon Therapeutics, Inc. has appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. She will serve until the company’s 2027 annual stockholder meeting, and will initially sit on the Board’s Compensation Committee.
Under the 2026 non-employee director compensation program, Ms. Francisco will receive an annual cash retainer of $50,000, paid quarterly, and an option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share. The option vests in 48 equal monthly installments, contingent on her continued Board service, and she has signed the company’s standard indemnification agreement.
Eikon Therapeutics filed a current report highlighting new clinical data and an updated corporate presentation. The company presented results from its Phase 2 TeLuRide-005 trial of EIK1001 in first-line stage 4 non-small cell lung cancer and its Phase 1/2 EIK1003 program in advanced solid tumors at the 2026 ASCO meeting.
In NSCLC, EIK1001 plus pembrolizumab and chemotherapy showed a 63.1% objective response rate and 90.8% disease control rate across 65 efficacy-evaluable patients, with the non-squamous cohort reaching a median duration of response greater than 11 months. EIK1003, a highly selective PARP1 inhibitor, produced objective responses both as monotherapy and in combination with weekly paclitaxel, with safety profiles described as generally consistent with expected toxicities and no treatment-related deaths reported.
Eikon Therapeutics reported first quarter 2026 results and detailed progress across its oncology pipeline. The company ended March 31, 2026 with $596 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2027.
R&D expenses rose to $70.0 million from $56.6 million, reflecting accelerating clinical trial activity and a $5.0 million milestone for advancing PARP1 inhibitor EIK1003 into Phase 2. G&A expenses increased to $17.3 million from $14.8 million, and net loss attributable to common stockholders widened to $83.0 million from $74.5 million. Eikon highlighted three priority programs—TLR7/8 agonist EIK1001, PARP1 inhibitor EIK1003, and WRN helicase inhibitor EIK1005—with multiple Phase 1/2 and Phase 2/3 trials and six ASCO 2026 abstracts accepted, underscoring growing clinical data across melanoma, lung, breast, ovarian, prostate, pancreatic, and MSI‑high tumors.
Eikon Therapeutics reported higher operating spending and losses for 2025 but ended the year with a much stronger cash position following its IPO. Research and development expenses rose to $250.3 million in 2025, up 22%, reflecting expanded clinical trial activity and its move into a new Millbrae headquarters.
General and administrative expenses increased to $88.6 million, mainly due to a $21.3 million asset impairment and higher compensation costs. Net loss attributable to common stockholders widened to $333.6 million, or $115.29 per share. Cash, cash equivalents, and marketable securities were $336.0 million at year-end, and a February 2026 upsized IPO raised an additional $381.2 million in gross proceeds, which the company expects will fund operations into the second half of 2027.
Eikon Therapeutics, Inc. reported that, in connection with the closing of its initial public offering on February 6, 2026, it put in place a new legal and governance framework. Immediately prior to the IPO closing, the company’s board and stockholders approved an amended and restated certificate of incorporation and amended and restated bylaws.
The restated certificate of incorporation was filed with the Delaware Secretary of State, and the updated bylaws became effective on February 6, 2026. These documents define the company’s capital structure and core governance rules as a newly public company whose common stock trades on the Nasdaq Stock Market under the symbol EIKN.